CAS: 3211-76-5; L-Selenomethionine

相似化合物

1464-42-2 1217852-49-7 1601474-63-8

上下游产品

(2S)-2-amino-4-(benzylselanyl)butanoic acid methyl iodide N-B°C-L-selenomethionine 2-Acetylamino-4-methylselanyl-butyric acidN-Acetylseleno-L-methionine N-B°C-L-selenomethionine N-(2,4-dinitrophenyl)seleno-L-methionine 15H22N6O5SeC15H22N6O5Se

N-Boc-L-Selenomethionine置于三氟乙酸体系中,用 二氯甲烷 作为反应溶剂,化学反应 0.5H,以96%的收率获得产物l-硒代蛋氨酸
参考文献:使用自由基链反应简捷合成l-硒代蛋氨酸和l-硒代胱氨酸
标题:使用自由基链反应简捷合成l-硒代蛋氨酸和l-硒代胱氨酸
摘要:L-硒代蛋氨酸和l-硒代胱氨酸分别以高产率从受保护的l-谷氨酸和l-天门冬氨酸衍生物制备.在二甲基二硒化物的存在下辐照衍生自(例如)的混合酸酐(酯)可直接提供被保护的l-硒代蛋氨酸.我们已经表明,三硒氰化物se 3(cn)2可以作为自由基的有效硒氰化剂.硒氰化物基团是l-硒代胱氨酸的二硒化物部分的非常好前体.
DOI:10.1016/s0040-4020(01)88049-2

专利信息

专利号:US-12351573-B2
优先权日:2019-05-09
标 题:Compounds for use in synthesis of peptidomimetics
发明人：AL-ABED YOUSEF; CHENG KAI FAN
权利人:FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
摘要:Synthesis of O-benzotriazole and O-imidazole synthons are described. Uses of synthons in synthesis of azapeptides and other peptidomimetics, azapeptides and other peptidomimetics synthesized from the synthons and uses of azapeptides and other peptidomimetics are also described.

专利号:US-2012177593-A1
优先权日:2009-07-20
标 题 :Synthesis of dendrimer conjugates
发明人：BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH
权利人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH; UNIV MICHIGAN
摘要:The present invention relates to novel methods of synthesis of therapeutic and diagnostic dendrimers. In particular, the present invention is directed to novel dendrimer conjugates, novel methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer, inflammatory disease) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer conjugates of the present invention may further comprise at least two different components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy. Furthermore, the novel synthesis methods of certain embodiments of the present invention provide significant advantages with regard to total reaction time and simplicity.

专利号:US-2023159450-A1
优先权日:2020-05-08
标 题 :Dimers for use in synthesis of peptidomimetics
发明人：AL-ABED YOUSEF; ALTITI AHMAD
权利人:FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
摘要:Dimers for use in synthesis of peptidomimetics are described. Uses of dimers as synthons in synthesis of azapeptides and other peptidomimetics, azapeptides and other peptidomimetics synthesized from the dimers and uses of azapeptides and other peptidomimetics are also described.

专利号:US-3983145-A
优先权日:1973-11-01
标 题:Use of alpha-di(lower alkoxy) anthraquinones in the synthesis of Alizarin Saphirols
发明人：WHITE DAVID L; FITZPATRICK JOSEPH W
权利人:TOMS RIVER CHEMICAL CORP
摘要:Alpha-dihydroxyanthraquinones used as intermediates in the synthesis of many dyestuffs, such as the Alizarin Saphirols (e.g. Color Constitution No. 63000, 63005, 63010, 63011, 63315 and 63610) can be replaced on an equimolar basis by alpha-di(lower alkoxy)anthraquinones. The alpha-di(lower alkoxy) anthraquinones can be converted in a single step, by treatment with oleum, to the corresponding alpha-dihydroxyanthraquinone-beta-disulfonic acids in almost quantitative yield. The corresponding diamine is obtained by dinitrating followed by reduction of the nitro groups. The known intermediate, leuco 1,4,5,8-tetrahydroxyanthraquinone (see C.I. No. 62500) can be obtained either by reduction of the diamine or by reduction of the dinitro compound. In one embodiment, the alpha-di(lower alkoxy)anthraquinone is obtained from dinitroanthraquinone by treatment thereof with methanol and KOH.

专利号:US-10427126-B2
优先权日:2015-10-28
标题 :System and method for longitudinal analysis of peptide synthesis
发明人：Bannen Ryan; Barilovits Sarah; PATEL JIGAR; SULLIVAN ERIC; TAN JOHN
权利人:ROCHE SEQUENCING SOLUTIONS INC
摘要:The present invention provides a system and method for assessing a synthetic peptide population including interrogating a population of peptide features in the presence of a receptor having an affinity for a binder sequence. The population of peptide features is synthesized over a plurality of synthesis periods and includes a plurality of control peptide features synthesized to have an amino acid sequence including the binder sequence. The control peptide features include a first feature synthesized beginning with a first one of the synthesis periods, and a second feature synthesized beginning after the first one of the synthesis periods such that synthesis of the second control peptide feature is delayed by at least one synthesis period. The method further includes detecting a signal output characteristic of an interaction of the receptor with the control peptide features, the signal output indicative of the fidelity of synthesis of the population of peptide features.

专利号:US-2007088086-A1
优先权日:1999-08-16
标题 :Method of using synthetic L-Se-methylselenocysteine as a nutriceutical and a method of its synthesis
发明人：SPALLHOLZ JULIAN E; REID TED W; WALKUP ROBERT D
权利人:PHARMASE INC
摘要:A synthesis of and use for L-Se-methylselenocysteine as a nutriceutical is described, based upon the knowledge that L-Se-methylselenocysteine is less toxic than L-selenomethionine towards normal cells. The synthesis proceeds by mixing N-(tert-butoxycarbonyl)-L-serine with a dialkyl diazodicarboxylate and at least one of a trialkylphosphine, triarylphosphine, and phosphite to form a first mixture that includes N-(tert-butoxycarbonyl)-L-serine β-lactone. Methyl selenol or its salt is mixed with the N-(tert-butoxycarbonyl)-L-serine β-lactone to form a second mixture that includes N-(tert-butoxycarbonyl)-Se-methylselenocysteine. The tert-butoxycarbonyl group is removed from the N-(tert-butoxycarbonyl)-Se-methylselenocysteine to form L-Se-methylselenocysteine. This synthesis significantly improves the manufacturability, manufacturing efficiency, and utility of this naturally occurring rare form of organic-selenium. L-Se-methylselenocysteine formed, for example, in this manner may be used as a nutriceutical for supplementation into the diets of humans or animals for various beneficial purposes, such as, for example, to prevent or reduce the risk of developing cancer.